What is ExQor Technologies?
ExQor Technologies, a Boston-based biotechnology firm, is at the forefront of developing a proprietary brain regenerative medicine platform. Their core focus is on reversing cognitive decline associated with Alzheimer's disease and other neurodegenerative disorders. A key innovation is their delivery technology, which effectively bypasses the blood-brain barrier, thereby enhancing treatment accessibility and potentially reducing overall healthcare expenditures. Beyond therapeutic development, ExQor is also advancing early detection capabilities for Alzheimer's, aiming for a holistic approach to disease management. The company's solutions target a significant global market, addressing the needs of the 55 million individuals currently living with dementia, with the ultimate goal of transitioning disease management towards disease reversal.
How much funding has ExQor Technologies raised?
ExQor Technologies has raised a total of $37K across 1 funding round:
Debt
$37K
Debt (2021): $37K with participation from PPP
Key Investors in ExQor Technologies
PPP
Public-Private Partnership
What's next for ExQor Technologies?
With significant Series B/C stage funding, ExQor Technologies is poised for accelerated growth and the scaling of its innovative regenerative medicine platform. The recent capital injection is expected to fuel further research and development, clinical trials, and the expansion of its early detection technologies. This strategic financing will likely enable ExQor to advance its pipeline candidates through critical regulatory milestones and prepare for potential commercialization, solidifying its position in the neurodegenerative disease therapeutics market.
See full ExQor Technologies company page
